2/11/2009

Seeking more information, the FDA postponed its decision on the use of Johnson & Johnson's Risperdal Consta to treat frequent mood swings in patients with bipolar disorder. The product received FDA clearance in 2003 as a twice-a-month treatment for schizophrenia.

Full Story:
Bloomberg, Forbes

Related Summaries